scispace - formally typeset
Open AccessJournal ArticleDOI

Executive summary of EPOS 2020 including integrated care pathways.

Reads0
Chats0
TLDR
The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012 and offers updated guidance for definitions and outcome measurements in research in different settings.
Abstract
The European Position Paper on Rhinosinusitis and Nasal Polyps 2020 is the update of similar evidence based position papers published in 2005 and 2007 and 2012(1-3). The core objective of the EPOS2020 guideline is to provide revised, up-to-date and clear evidence-based recommendations and integrated care pathways in ARS and CRS. EPOS2020 provides an update on the literature published and studies undertaken in the eight years since the EPOS2012 position paper was published and addresses areas not extensively covered in EPOS2012 such as paediatric CRS and sinus surgery. EPOS2020 also involves new stakeholders, including pharmacists and patients, and addresses new target users who have become more involved in the management and treatment of rhinosinusitis since the publication of the last EPOS document, including pharmacists, nurses, specialised care givers and indeed patients themselves, who employ increasing self-management of their condition using over the counter treatments. The document provides suggestions for future research in this area and offers updated guidance for definitions and outcome measurements in research in different settings.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Epithelial barriers in allergy and asthma.

TL;DR: The current understandings of epithelial barrier defects in type 2–driven chronic inflammation of the upper and lower airways are reviewed, the estimated contribution of these novel identified epithelial cells to disease are estimated, and the current clinical challenges in relation to diagnosis and treatment of allergic rhinitis, chronic rhinosinusitis, and asthma are discussed.
Journal ArticleDOI

Epidemiology of chronic rhinosinusitis: prevalence and risk factors.

TL;DR: A review of the current evidence on the epidemiology of chronic rhinosinusitis (CRS) with a focus on prevalence and risk factors is presented in this article , where the authors suggest that the true prevalence of CRS is consistently less than 5%, with approximately one-third of patients with CRS having nasal polyps.
Journal ArticleDOI

Recent Insights into the Management of Inflammation in Asthma.

TL;DR: A growing body of real-world evidence on the predominant T2-high nature of severe asthma is emerging as discussed by the authors, and the evolving understanding of T2 driven inflammation alongside a treatable traits disease model is enhancing therapeutic approaches to address inflammation in asthma.
Journal ArticleDOI

Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?

TL;DR: In this paper, the authors discuss whether treatment with biological agents is equally effective in controlling both asthma and sinonasal symptoms in patients in which asthma and chronic rhinosinusitis with nasal polyps coexist.
Journal ArticleDOI

Pediatric Versus Adult Chronic Rhinosinusitis

TL;DR: The similarities and differences between pediatric and adult CRS are reviewed and low-dose macrolides are used for immunomodulatory activities and beneficial effects to adult patients with CRSsNP were demonstrated by recent meta-analyses.
Related Papers (5)